Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024

March 7, 2024 4:15 PM

Conference Call AlertPLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 7, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).MorphoSys' Management team will host a conference call and webcast on March 14, 2024, at 01:00 pm CET (12:00 pm GMT; 08:00 am EDT) to present the results for the financial year 2023 and provide an outlook for 2024.The...

Read more

RETRANSMISSION: Organicell Regenerative Medicine Rebranding to ZEO ScientifiX

March 7, 2024 12:25 PM

Leading Therapeutics Research Company Begins New EraCommon Stock to trade on OTCQB under the symbol "ZEOX" commencing March 5, 2024FORT LAUDERDALE, FL / ACCESSWIRE / March 7, 2024 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) (f/k/a Organicell Regenerative Medicine, Inc. - OTCQB:OCEL) today reported that the Financial Industry Regulatory Agency ("FINRA") completed the processing of the Company's Corporate Action Notification Form filed with respect to the...

Read more

Lexaria Awards Contract For Next GLP-1 Human Pilot Study

March 7, 2024 9:05 AM

First-ever dissolvable DehydraTECH-GLP-1 oral dose formulation to be testedRybelsus® semaglutide will act as the positive controlKELOWNA, BC / ACCESSWIRE / March 7, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has hired a contract research organization ("CRO") to perform the Company's second DehydraTECH-powered glucagon-like peptide 1...

Read more

Edesa Biotech to Participate in Barclays Global Healthcare Conference

March 7, 2024 8:45 AM

TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that company management will participate in the Barclays 26th Annual Global Healthcare Conference, which is being held in Miami, Florida, from March 12-14, 2024.Attendees interested in meeting with Edesa can request meetings...

Read more

AbTherx Appoints Janine Schuurman, PhD, as Scientific Advisor

March 7, 2024 6:00 AM

Antibody expert and co-inventor of DuoBody®, HexaBody®, and HexElect® technologies joins AbTherx to drive expansion of the Atlas™ Mice platformMOUNTAIN VIEW, CA / ACCESSWIRE / March 7, 2024 / AbTherx, Inc., a biotechnology company with innovative technologies that enable and accelerate antibody discovery, today announced the appointment of Janine Schuurman, PhD, as a scientific advisor. In her new role, Dr. Schuurman will provide guidance on the...

Read more

Biovica Signs Master Service Agreement for TKa Testing with Leading Pharma Company

March 7, 2024 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / March 7, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in blood-based cancer monitoring, has signed a master service agreement with a leading tier-1 pharmaceutical company, enabling Biovica to provide its TKa testing assay and testing services. The agreement holds room for several expected work orders, the first of which is 1.7 MSEK.This service agreement enables the evaluation...

Read more

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting

March 6, 2024 8:40 AM

97% of VenoValve Study Patients Showing Clinical Improvement at Six Months (as Measured by the Revised Venous Clinical Severity Score (rVCSS))74% of the Study Patients Showing Clinical Meaningful Benefit from the VenoValve at Six Months (Improvement in rVCSS of 3 or More Points)Average rVCSS Improvement Per Patient is 8 Points, More Than Two and a Half Times the Amount Needed to Show the VenoValve's Clinically Meaningful BenefitCompany on Track...

Read more

Moolec Science to Host Second Quarter Fiscal Year 2024 Business Update Conference Call

March 6, 2024 8:00 AM

LUXEMBOURG / ACCESSWIRE / March 6, 2024 / Moolec Science SA (NASDAQ:MLEC) ("Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, announced today that it will release its Business Update for the Second Quarter Fiscal Year 2024 on Wednesday, March 13, 2024, before the market opens. logo Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José...

Read more

Innoveren Scientific Announces 510(k) Submission for SkinDisc(TM) Lite

March 6, 2024 8:00 AM

First Commercial Product Submission from Company's Robust Regenerative Medicine-Based PipelineCINCINNATI, OH / ACCESSWIRE / March 6, 2024 / Innoveren Scientific Inc. (OTCQB:IVRN) ("Innoveren" or the "Company"), a life science company focused on becoming a leading biotech incubator, announced today that it has submitted a 510(k) premarket filing to the U.S. Federal Food and Drug Administration (FDA) for its SkinDiscTM Lite product.SkinDiscTM Lite...

Read more

InDevR Launches Expert Services to Address Vaccine Development Challenges

March 5, 2024 1:30 PM

BOULDER, CO / ACCESSWIRE / March 5, 2024 / InDevR Inc., a global leader in vaccine analytical tools and method development, is excited to announce the launch of its latest offering, Expert Services. Expert Services provides vaccine manufacturers with tailored workflow solutions to help address and eliminate development bottlenecks and accelerate the analysis and validation of seasonal vaccines and novel biotherapeutics.Expert Services is...

Read more

assisTek Celebrates 25 Years of Pioneering Innovation in eClinical Patient Data for Clinical Research Trials

March 5, 2024 10:00 AM

25 Years of Excellence: assisTek Acknowledges Contributions to a Quarter-Century of SuccessDOYLESTOWN, PA / ACCESSWIRE / March 5, 2024 / assisTek, a trailblazer in eClinical patient data solutions, proudly commemorates a significant milestone: 25 years of revolutionizing the landscape of clinical research trials.Since its inception in 1998, assisTek has been at the forefront of empowering researchers with cutting-edge technologies and...

Read more

Radiance Therapeutics to Attend LSI USA '24 Emerging Medtech Summit in Dana Point, CA

March 5, 2024 9:00 AM

EMERYVILLE, CA / ACCESSWIRE / March 5, 2024 / Radiance Therapeutics, Inc. (RadianceTx®), an innovation leader in ophthalmic devices, is delighted to announce that its CEO, Laurence Marsteller MD, will be representing the company at the LSI USA '24 Emerging Medtech Summit, which will take place on March 18-22, 2024 in Dana Point, California.LSI USA ‘24 is a unique conference that brings together the most innovative emerging medtech players and...

Read more

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

March 5, 2024 8:31 AM

Tharimmune invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth ConferenceBRIDGEWATER, NJ / ACCESSWIRE / March 5, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology is pleased to announce that it has been...

Read more

Edesa Biotech to Participate in Upcoming Dermatology Meetings

March 4, 2024 4:30 PM

TORONTO, ON / ACCESSWIRE / March 4, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company plans to participate in the American Contact Dermatitis Society Annual Meeting on March 7, 2024 and the American Academy of Dermatology Annual Meeting from March 8-12, 2024 in San Diego, California.Attendees...

Read more

Organicell Regenerative Medicine Rebranding to ZEO ScientifiX

March 4, 2024 4:15 PM

Leading Therapeutics Research Company Begins New EraCommon Stock to trade on OTCQB under the symbol "ZEOX" commencing March 5, 2024FORT LAUDERDALE, FL / ACCESSWIRE / March 4, 2024 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) (f/k/a Organicell Regenerative Medicine, Inc. - OTCQB: OCEL) today reported that the Financial Industry Regulatory Agency ("FINRA") completed the processing of the Company's Corporate Action Notification Form filed with respect to...

Read more

Adolore BioTherapeutics Announces Issuance of First U.S. Patent Covering CA8* Gene Therapies to Treat Chronic Pain

March 4, 2024 10:00 AM

Patent and CA8* gene therapy technology licensed by Adolore BioTherapeutics from the University of MiamiCompany advancing development of rdHSV-CA8* gene therapy for the treatment of chronic osteoarthritis (OA) knee pain toward an INDDELRAY BEACH, FL / ACCESSWIRE / March 4, 2024 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain,...

Read more

Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment

March 4, 2024 6:20 AM

Berlin Cures, a clinical-stage biotechnology firm, advances innovative treatment aimed at combating Long COVID, currently impacting over 100 million people globally. Over 50% of patients in randomized placebo-controlled Phase-II-trial now recruited; no issues regarding safety observed. Berlin Cures innovative platform develops novel aptamer-based drugs to neutralize pathogenic functional autoantibodies, targeting diseases. BERLIN, GERMANY /...

Read more

AbTherx Announces Transition from Early Access to Commercialization of its Bispecific and Full Human Diversity Antibody Discovery Technologies

March 4, 2024 6:00 AM

Atlas™ Mice can now be evaluated by pharmaceutical and biotech companies and accessed through a network of preferred service providersMOUNTAIN VIEW, CA / ACCESSWIRE / March 4, 2024 / AbTherx, a biotechnology company with innovative technologies that enable and accelerate antibody discovery, today announced expanded commercialization of its bispecific and full human diversity antibody discovery technologies. After an initial successful launch...

Read more

MRES: M2Bio Sciences Provides Corporate Update

March 1, 2024 9:10 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 1, 2024 / Institute of Biomedical Research Corporation (OTC PINK:MRES) is pleased to provide further details of the sale to Real American Capital Corporation (OTC PINK:RLAB) of 100% ownership of the concept, business model, contacts and contracts that collectively can be used to establish a mixed martial arts league and are herein referred to as "M2MMA" (https://m2mma.com).The transaction was...

Read more

NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders

March 1, 2024 9:00 AM

CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business developments, financing and the 2024 annual meeting.The previously disclosed $10.7 million financing transaction with Sumner Global LLC remains pending, as Sumner Global has not yet obtained the funding necessary to close the transaction. To provide...

Read more